EUVIMEDEUVIMED entdecken
Crossref

A novel anti-IL-33 antibody recognizes an epitope FVLHN of IL-33 and has a therapeutic effect on inflammatory diseases

Shixin Duan, Jun Wang, Xinyi Lou, Dongxin Chen, Peiyunfeng Shi, Hongchao Jiang, Zhiming Wang, Wen Li, Feng Qian

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Shixin Duan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, PR…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Asthma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a crucial member of the Interleukin-1 (IL-1) family, IL-33 plays an indispensable role in modulating inflammatory responses. Here, we developed an effective anti-human IL-33 monoclonal antibody (mAb) named 5H8. Importantly, we have identified an epitope (FVLHN) of IL-33 protein as a recognition sequence for 5H8, which plays an important role in mediating the biological activity of IL-33. We observed that 5H8 significantly suppressed IL-33-induced IL-6 expression in bone marrow cells and mast cells in a dose-dependent manner in vitro. Furthermore, 5H8 effectively relievedHDM-induced asthma and PR8-induced acute lung injury in vivo. These findings indicate that targeting the FVLHN epitope is critical for inhibiting IL-33 function. In addition, wedetected that the Tm value of 5H8 was 66.47℃ and the KD value was 173.0 pM, which reflected that 5H8 had good thermal stability and high affinity. Taken together, our data suggest that our newly developed 5H8 antibody has potential as a therapeutic antibody for treating inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAsthmaHumansEpitopesInterleukin-1

Stichwörter der Autor:innen

Acute lung injuryAsthmaEpitopeInterleukin-33monoclonal antibody

Substanzen

EpitopesAntibodies, MonoclonalInterleukin-1

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, PR China; Engineering Research Center of Cell & Therapeutic Antibody, Mi…
  • Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, PR China; Xiamen Innovax Biotech Co, Xiamen, Fujian 361005, PR China.
  • Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, PR China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Duan, S., Wang, J., Lou, X., Chen, D., Shi, P., Jiang, H., Wang, Z., Li, W., & Qian, F. (2023). A novel anti-IL-33 antibody recognizes an epitope FVLHN of IL-33 and has a therapeutic effect on inflammatory diseases. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110578

Vancouver

Duan S, Wang J, Lou X, Chen D, Shi P, Jiang H, et al. A novel anti-IL-33 antibody recognizes an epitope FVLHN of IL-33 and has a therapeutic effect on inflammatory diseases. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110578

BibTeX
@article{Duan2023,
  author = {Duan, Shixin and Wang, Jun and Lou, Xinyi and Chen, Dongxin and Shi, Peiyunfeng and Jiang, Hongchao and Wang, Zhiming and Li, Wen and Qian, Feng},
  title = {A novel anti-IL-33 antibody recognizes an epitope FVLHN of IL-33 and has a therapeutic effect on inflammatory diseases},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110578}
}
Kostenlos starten →